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Journal, a study by Burgers et al. [3] investigated the treat-
ment variation in stent choice (BMS vs. DES) in patients 
with stable and unstable CAD across 4 medical centres in 
the Netherlands. This study is a sub-analysis of the CIRCU-
LATING CELLS study that included patients from March 
2009 until September 2011 and aimed to discover markers 
to predict future cardiovascular events. Overall, 66 % of 
442 patients were treated with DES with no difference of 
DES use between stable (n = 358) or unstable CAD patients 
(n = 84). Increased use of DES was associated with NYHA 
class, smoking, multivessel disease, previous PCI, diabetes 
mellitus, and interestingly treating hospital which explained 
33 % of the variation in stent choice. DES use in patients 
varied widely between hospitals, ranging from 50 to 99 %. 
The increased use of DES in certain patient groups largely 
followed the guidelines, because DES is considered most 
useful in patients at risk for restenosis. However, the varia-
tion of DES use between hospitals is curious and not imme-
diately explained by differences in patient case mix. What 
then, explains this unwarranted variation in stent choice?
To understand unwarranted variation in medical practice, 
different areas need to be considered [4]. First, underuse of 
effective (evidence-based) PCI care will likely be small but 
cannot be ignored despite appropriate training and skills. It 
is known that underuse of evidence-based medicine can be 
attenuated when doctors practice team medicine, i.e. in a 
Heart Team. Providing and adapting state-of-the-art care in 
large rural areas is more difficult than in densely populated 
urban areas. Second, the largest variation may be explained 
by preference-sensitive care. Here, more than one gener-
ally accepted treatment option is available and the variation 
largely depends on differences in opinion between cardiolo-
gists. Because DES are so effective in reducing restenosis, 
many cardiologists have adopted DES for ‘off-label’ indica-
tions and ‘consume’ more DES than others. Here, patient 
The primary aim of treating patients with coronary artery 
disease (CAD) is to reduce symptoms and improve prog-
nosis, which encompasses risk factor modification and 
pharmacological management. Coronary artery bypass 
grafting (CABG) and percutaneous coronary interven-
tion (PCI) using bare-metal stents (BMS) and drug-eluting 
stents (DES) have become established additional treat-
ment options. PCI is undoubtedly the preferred reperfusion 
therapy for ST-elevation myocardial infarction (STEMI), 
but optimal treatment for complex non-STEMI and stable 
CAD is less well established. Whether optimal medical 
therapy, PCI, or CABG is preferred in this complex group 
of patients depends on the risk-benefit ratios of these treat-
ment strategies and should be discussed in multidisciplinary 
teams (Heart Team) [1]. While DES are more effective in 
reducing restenosis than BMS and target-vessel revasculari-
sation (TVR, estimated reduction 50–70 %), DES are more 
costly and require prolonged dual antiplatelet therapy that 
increases bleeding complications. The benefits of DES use 
are greatest in patients at the highest risk of TVR [2].
Ideally, a country’s healthcare system should guarantee 
that all patients receive optimal medical care, independent 
of their welfare status or whatever hospital they are referred 
to. When standards of care are clear, there should be no 
variation in practice across the country. With the expansion 
of interventional centres in the Netherlands a rather com-
plete geographical spread has been reached, but whether 
treatment disparities exist between centres has largely been 
unknown. In the current issue of the Netherlands Heart 
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preferences and shared decision-making have shown to 
improve the quality of care and attenuate medical practice 
variation. Third, supply-sensitive care describes the avail-
able resources that may differ between hospitals as a result 
of differing hospital contracts with health insurance com-
panies, stent producing companies, budgetary constraints, 
financial incentives, etc.
Recruitment of study patients took place during a transi-
tion period of advanced and more expensive DES technol-
ogy with newer drug coatings that gradually and increasingly 
replaced BMS. Because the study spans only 2 years, differ-
ences between cardiologists as either early adopters or late 
believers of new technology more clearly affect differences 
in stent choice than when a longer period was studied. As it 
happens over time and when evidence and experience have 
sufficiently been build up, differences between cardiolo-
gists, hospitals and material costs are likely to decrease.
Nonetheless, Burgers et al. are to be congratulated, 
because they are the first to show a hospital-dependent varia-
tion of DES use in the Netherlands, where geographical dif-
ferences should not be an issue. Hospital differences in DES 
use have been shown in other parts of the world as well. In 
the United States, DES use has been shown to vary widely 
among physicians with only a modest correlation to patients’ 
risk of restenosis [5]. Reducing DES use among patients at 
low TVR risk may substantially lower healthcare costs with 
only a minimal increase in TVR. However, before jumping 
to conclusions, an important question remains unanswered: 
does practice variation matter? Knowing whether hospital 
and geographical variations in the use of DES affects out-
come would help in defining the most optimal treatment 
strategy that improves prognosis and is cost-effective. With 
this study, an important first step has been taken by creating 
awareness of regional variations in stent choice in the Neth-
erlands. We now have to take this message one step further 
and investigate whether this affects outcome.
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